
浏览全部资源
扫码关注微信
1.北京中医药大学东直门医院急诊科,北京 100700
2.北京中医药大学国学院,北京 100029
3.北京中医药大学东方医院感染科,北京 100078
孙玲玲,女,26岁,硕士研究生。研究方向:名老中医经验传承。
李雁,E-mail:13011097949@126.com
纸质出版日期:2024-12-25,
收稿日期:2024-03-29,
移动端阅览
孙玲玲,李雁,陈一凡,等.秦伯未从“虚、郁、瘀、水”辨治肝硬化经验[J].北京中医药,2024,43(12):1396-1400.
SUN Lingling,LI Yan,CHEN Yifan,et al.QIN Bowei's experience in differentiating and treating liver cirrhosis from the perspective of "deficiency, depression, stasis, and water"[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(12):1396-1400.
孙玲玲,李雁,陈一凡,等.秦伯未从“虚、郁、瘀、水”辨治肝硬化经验[J].北京中医药,2024,43(12):1396-1400. DOI: 10.16025/j.1674-1307.2024.12.013.
SUN Lingling,LI Yan,CHEN Yifan,et al.QIN Bowei's experience in differentiating and treating liver cirrhosis from the perspective of "deficiency, depression, stasis, and water"[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(12):1396-1400. DOI: 10.16025/j.1674-1307.2024.12.013.
秦伯未先生认为肝硬化总属本虚标实之证,结合其病理演变过程,总结“虚、郁、瘀、水”为其核心要素,四者在病程中互为因果,各有侧重。其中,“虚”为本,故治疗以“扶正”为基础并贯穿始终;“郁”为要,治以“疏肝和络”;“瘀”为枢,辨其轻重予以“和络消癥”;“水”为标,治以“利尿泻水”为主。
肝硬化中医药虚郁瘀水
GINES P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021,398(10308):1359-1376.
GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2020,5(3):245-266.
PENG CY, CHIEN RN, LIAW YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy[J]. J Hepatol, 2012,57(2):442-450.
LI H. Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula[J]. J Ethnopharmacol, 2020,251:112442.
XIE Z, QIANG J, PI X, et al. Favorable outcome of adjunctive traditional Chinese medicine therapy in liver cirrhosis: A large cohort study in Southwest China[J]. Complement Ther Med, 2020,51:102446.
秦伯未.中医入门[M].北京:人民卫生出版社,2006:62.
秦伯未.秦伯未增补谦斋医学讲稿[M].北京:中国医药科技出版社,2014.
曾燕鹏,李雁,陈一凡,等.从“病所-病因-病态”探析秦伯未对补中益气汤方证之认识[J].环球中医药,2020,13(12):2141-2144.
孙其新.谦斋五行生克辨证法则:当代名医秦伯未辨证论治精华(17)[J].辽宁中医杂志,2004,31(1):8-10.
李菲.肝硬化患者的中医体质调查研究与分析[D].南宁:广西中医药大学,2023.
HUI Y, LI N, YU Z, et al. Health-related quality of life and its contributors according to a preference-based generic instrument in cirrhosis[J]. Hepatol Commun, 2022,6(3):610-620.
VAUGHN-SANDLER V, SHERMAN C, ARONSOHN A, et al. Consequences of perceived stigma among patients with cirrhosis[J]. Dig Dis Sci, 2014,59(3):681-686.
袁振华,刘苗苗,张蔷,等.基于“从化”与“通络”思想探析儿童抽动障碍因机证治[J].北京中医药,2024,43(1):82-84.
孙学刚,黎春华,吕志平.肝主疏泄与肝窦内皮功能关系探讨[J].中国中医基础医学杂志,2010,16(5):373-375.
TRIPODI A, PRIMIGNANI M, MANNUCCI PM, et al. Changing concepts of cirrhotic coagulopathy[J]. Am J Gastroenterol, 2017,112(2):274-281.
谭春雨,刘平.肝硬化“虚损生积”病机理论溯源及其临床意义[J].上海中医药大学学报,2010,24(4):25-28.
王永生.逍遥散与四逆散合方辨治肝硬化[J].中国民族民间医药,2012,21(19):88.
吴丹,高耀,向欢,等.基于网络药理学的柴胡抗抑郁作用机制研究[J].药学学报,2018,53(2):210-219.
张明远,许二平,陈毅恒,等.柴胡治疗抑郁症药理作用研究现状[J].中华中医药学刊,2023,41(10):102-108.
黄灿,沈垚村,刘深梵,等.基于“肝-胆汁酸-肠道菌群轴”论非酒精性脂肪性肝病肝郁脾虚病机的生物学内涵[J].北京中医药,2023,42(5):551-555.
王佳俊,向世勰,谢治深,等.黄芪化学成分抗纤维化作用及分子机制研究进展[J].中药新药与临床药理,2023,34(12):1799-1805.
林稼樱,曹云,黄佳钦,等.基于网络药理学探讨丹参治疗肝纤维化的作用机制[J].北京中医药,2021,40(5):542-545.
徐佳新,许浚,曹勇,等.中药白芍现代研究进展及其质量标志物的预测分析[J].中国中药杂志,2021,46(21):5486-5495.
李力恒,陈丽萍,胡晓阳,等.柴胡的化学成分及药理作用研究进展[J].中医药学报,2023,51(2):109-112.
马燕,张育贵,石露萍,等.当归炮制品及其化学成分和药理作用研究进展[J].中国中药杂志,2023,48(22):6003-6010.
刘思佳,姚杰,宋雪,等.苍术属药用植物的化学成分、药理作用、临床应用概况[J].中华中医药学刊,2023,41(1):151-154.
LIU HL, LYU J, ZHAO ZM, et al. Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis[J]. Sci Rep, 2019,9(1):18719.
齐婧姝,王宇,刘成海.活血化瘀法在肝硬化中医药治疗中的实践应用与发展[J].上海中医药杂志,2023,57(8):27-32.
吴晓明,何强,尤圣杰,等.中药复方抗肝纤维化作用机制研究概述[J].北京中医药,2021,40(6):675-680.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备 11010102006710号